Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
132 hedge funds and large institutions have $2.17B invested in Juno Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 54 increasing their positions, 28 reducing their positions, and 56 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 28
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
14% less funds holding
Funds holding: 154 → 132 (-22)
14% less capital invested
Capital invested by funds: $2.54B → $2.17B (-$365M)
34% less call options, than puts
Call options by funds: $29.5M | Put options by funds: $44.9M
38% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 56
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$131M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$37.5M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$29M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$16.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$15.6M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$14.9M |
| 4 |
JP Morgan Chase
New York
|
-$13.2M |
| 5 |
DM
Deerfield Management
New York
|
-$9.77M |
JUNO Hedge Fund Activity: Q3 2015 in Review
132 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q3 2015, worth a combined $2.17B — down 14% from $2.54B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of JUNO and 35 opened new positions — a net loss of 21 holders — while 28 trimmed existing stakes and 54 added.
The largest buyer was Vanguard Group, adding an estimated $131M. The largest seller was Lord, Abbett & Co, cutting an estimated $16.3M.
- 132 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q3 2015, down from 154 in Q2 2015.
- Funds reported $2.17B of Juno Therapeutics, Inc. stock for Q3 2015, down 14% quarter-over-quarter.
- 35 funds opened new Juno Therapeutics, Inc. positions in Q3 2015 and 56 closed out, a net change of -21 holders.
- The largest Juno Therapeutics, Inc. buyer in Q3 2015 was Vanguard Group, an estimated $131M added.
- The largest Juno Therapeutics, Inc. seller in Q3 2015 was Lord, Abbett & Co, an estimated $16.3M sold.
Based on aggregated 13F filings for Q3 2015.